ARSファーマシューティカルズ
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.63 | $34M | -$61M |
| 2026 Q1 | -0.61 | $23M | -$45M |
| 2025 Q4 | -0.42 | $28M | -$43M |
| 2025 Q3 | -0.52 | $33M | -$47M |
| 2025 Q2 | -0.46 | $16M | -$40M |
| 2025 Q1 | -0.35 | $8M | -$41M |
| 2024 Q4 |
| 0.51 |
| $87M |
| $42M |
| 2024 Q3 | -0.20 | $2M | -$15M |